Resultados de la búsqueda 991-1000 of 17126 for decrease same center

  1. Ensayos clínicos - Medicina interna general

    The purpose of this study is test the effectiveness of the senolytic drug (Fisetin) in reducing senescent cell abundance in blood in elderly adults. EMU.

  2. Recuento de calorías: recurra a los principios básicos para bajar de peso - Mayo Clinic

    El control del peso realmente se reduce a una cosa: las calorías. ... Centers for Disease Control and Prevention. www ... FoodData Central. U.S. ...

  3. Ensayos clínicos - Neurología

    Arizona Alzheimer's Disease Research Center (ADRC-001) ... decline (e.g., Mueller et al, 2018). We propose ... central nervous system (CNS). A Study to ...

  4. Ensayos clínicos - Neurología

    ... reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...

  5. Ensayos clínicos - Neurología

    ... reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...

  6. Neurología - Ensayos clínicos

    If cognitive decline can be reversed in these patients, then we will have established a new indication for carotid revascularization independent of the risk of ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    However, the use of anti-inflammatory agents in the prevention of colorectal cancer is controversial, although there is some suggestion that its use may lower ...

  8. Ensayos clínicos - Neurología

    The purpose of the study is to learn more about inflammatory diseases of the central nervous system (CNS) by collecting patient information, blood sample (which ...

  9. Neurología - Ensayos clínicos

    If cognitive decline can be reversed in these patients, then we will have established a new indication for carotid revascularization independent of the risk of ...

  10. Ensayos clínicos - Neurología

    ... reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...